

United States Patent and Trademark Office
- Sales Receipt -

05/12/2006 LHUMES 00000005 031181 10721144

01 FC:1806 180.00 DA

RECEIVED
CENTRAL FAX CENTER

MAY 05 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

By: Robert J. HARIRI Confirmation No.: 6313

Serial No.: 10/721,144 Art Unit: 1636

Filed: 25 November 2003 Examiner: McGillem, Laura

For: CYTOTHERAPEUTICS, Attorney Docket No.: ANTH-0004
CYTOTHERAPEUTIC UNITS, AND
METHODS FOR TREATMENTS USING
THEM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. § 1.56, there is hereby provided certain information that the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
- 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of:
 - ☒ Each U.S. patent application publication and foreign patent, except those U.S. patent application publications not required to be submitted;
 - ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
 - ☒ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
 - ☒ all other information or portion which caused it to be listed on the PTO-1449.
 - 1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
 - 1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

BEST AVAILABLE COPY

RECEIVED
CENTRAL FAX CENTER

MAY 05 2006

6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).
- (Check appropriate items 6a, 6b and/or 6c)*
- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement.
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
- (Check Item 8a, 8b, or 8c)*
- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Celgene Corporation Deposit Account No. 031181.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability. No admission is made that a search has been undertaken (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§ 1.97 (g) and (h).

Respectfully submitted,

Richard T. Girards, Jr.
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
(908) 673-954352,946
(Reg. No.)

Date: 10 April 2006

BEST AVAILABLE COPY